Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III open-label single-arm trial of RTX-GRT7039 intra-articular injection for knee osteoarthritis pain
jRCT2031230069Phase 3Completed
- Sponsor
- Grünenthal GmbH
- Start
- Jul 2023
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
01
Overview
Phase 3, open-label, single-arm trial of RTX-GRT7039 in knee osteoarthritis (OA), sponsored by Grünenthal GmbH. Primary endpoint: Incidence of treatment-emergent adverse events (TEAEs) and TEAEs leading to discontinuation. Started Jul 2023; status: completed.
02
Drugs
RTX-GRT7039
03
Conditions
knee osteoarthritis (OA)
Beyond the preview
Go deeper on jRCT2031230069.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031230069.